• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Luna Innovations Reports Strong Fourth-Quarter and Full-Year 2022 Results

    3/14/23 4:05:00 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email

    Provides 2023 Guidance

    Q4 Financial Highlights

    • Revenues of $31.7 million, up 31% year over year
      • Revenues in constant currency of $32.5 million; up 34% year over year
    • Gross margin of 61%, compared to 58% for the prior year
    • Net income of $0.9 million, compared to net income of $1.6 million for the prior year
    • Adjusted EBITDA of $4.7 million, compared to $3.1 million for the prior year
    • Adjusted EPS of $0.08, compared to $0.08 for the prior year

    Full-Year Financial Highlights

    • Revenues of $109.5 million, up 25% year over year
      • Revenues in constant currency of $111.9 million; up 28% year over year
    • Gross margin of 61%, compared to 59% for the prior year
    • Net income of $9.3 million, compared to net income of $1.4 million for the prior year
    • Adjusted EBITDA of $12.1 million, compared to $7.6 million for the prior year
    • Adjusted EPS of $0.21, compared to $0.17 for the prior year

    Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced optical technology, today announced its financial results for the three months and full fiscal year ended December 31, 2022.

    "2022 was a transformational year for Luna representing the culmination of execution on the five-year strategic plan we outlined in 2017, thereby creating a pure-play fiber optics company," said Scott Graeff, President and Chief Executive Officer of Luna. "We've moved into FY23 with keen focus and high expectations for organizational optimization, large customer wins, and market expansion.

    "With the completed divestiture of Luna Labs, our acquisition of Lios Sensing, and the integration of OptaSense, we created a solid base that reflects our fiber-focused vision for our business going forward. We believe these accomplishments will help us deliver strong financial results in FY23 and will enable our success far into the future.

    "We are creating a leading global organization with world-class capabilities," Graeff continued. "With the right people in the right places in a right-sized organization, we are preparing for significant scalability and targeting meaningful growth. We are looking forward to a strong year in an expanding market with incredible potential."

    Fourth-Quarter Fiscal 2022 Financial Summary

    Highlights of the financial results for the three months ended December 31, 2022 are:

     

     

    Three Months Ended December 31,

     

    Change

    (in thousands, except share and per share data)

     

     

    2022

     

     

     

    2021

     

     

     

    Revenues

     

    $

    31,702

     

     

    $

    24,222

     

     

    31

    %

     

     

     

     

     

     

    Gross profit

     

     

    19,335

     

     

     

    14,120

     

     

    37

    %

    Gross margin

     

     

    61

    %

     

     

    58

    %

     

     

     

     

     

     

     

     

    Operating expense

     

     

    17,871

     

     

     

    13,085

     

     

    37

    %

    Operating income

     

     

    1,464

     

     

     

    1,035

     

     

     

     

    Operating margin

     

     

    4.6

    %

     

     

    4.3

    %

     

     

     

     

     

     

     

     

     

     

    Other (expense)/income and income tax (expense)/benefit

     

     

    (647

    )

     

     

    440

     

     

     

     

     

     

     

     

     

     

     

     

    Net income from continuing operations

     

    $

    817

     

     

    $

    1,475

     

     

     

     

     

     

     

     

     

     

     

     

    Income from discontinued operations, net of income taxes of $500 and $203

     

     

    36

     

     

     

    100

     

     

     

     

     

     

     

     

     

     

     

     

    Net income

     

    $

    853

     

     

    $

    1,575

     

     

     

     

     

     

     

     

     

     

     

     

    Earnings per diluted share (EPS)

     

    $

    0.02

     

     

    $

    0.05

     

     

     

     

    Adjusted EPS

     

    $

    0.08

     

     

    $

    0.08

     

     

    —

    %

    Diluted weighted average shares outstanding

     

     

    34,354,984

     

     

     

    33,665,613

     

     

     

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA

     

    $

    4,692

     

     

    $

    3,123

     

     

    50

    %

    A reconciliation of Adjusted EPS and Adjusted EBITDA to the nearest comparable figures under generally accepted accounting principles ("GAAP") can be found in the schedules included in this release.

    Revenues for the three months ended December 31, 2022 increased 31% compared to the prior year period; 34% in constant currency.

    Gross margin for the three months ended December 31, 2022 was 61%, compared to 58% for the three months ended December 31, 2021, driven primarily by product mix. Operating income increased to $1.5 million for the three months ended December 31, 2022, compared to $1.0 million for the three months ended December 31, 2021.

    Net income was $0.9 million, or $0.02 per fully diluted share, for the three months ended December 31, 2022, compared to $1.6 million, or $0.05 per fully diluted share, for the three months ended December 31, 2021. Adjusted EPS was $0.08 for the three months ended December 31, 2022 compared to $0.08 for the three months ended December 31, 2021.

    Adjusted EBITDA was $4.7 million for the three months ended December 31, 2022, compared to $3.1 million for the three months ended December 31, 2021.

    Full-Year Fiscal 2022 Financial Summary

    Highlights of the financial results for the year ended December 31, 2022 are:

     

     

    Full Year Ended December 31,

     

     

    (in thousands, except share and per share data)

     

     

    2022

     

     

     

    2021

     

     

    Change

    Revenues

     

    $

    109,497

     

     

    $

    87,513

     

     

    25

    %

     

     

     

     

     

     

     

    Gross profit

     

    $

    66,497

     

     

    $

    51,556

     

     

    29

    %

    Gross margin

     

     

    61

    %

     

     

    59

    %

     

     

     

     

     

     

     

     

     

    Operating expense

     

     

    68,381

     

     

     

    54,146

     

     

    26

    %

    Operating loss

     

     

    (1,884

    )

     

     

    (2,590

    )

     

     

     

    Operating margin

     

     

    (1.7

    )%

     

     

    (3.0

    )%

     

     

     

     

     

     

     

     

     

     

    Other (expense)/income and income tax benefit

     

     

    (416

    )

     

     

    1,501

     

     

     

     

     

     

     

     

     

     

     

    Net loss from continuing operations

     

    $

    (2,300

    )

     

    $

    (1,089

    )

     

     

     

     

     

     

     

     

     

     

    Income from discontinued operations, net of income taxes $3,705 and $584

     

     

    11,579

     

     

     

    2,471

     

     

     

     

     

     

     

     

     

     

     

     

    Net income

     

    $

    9,279

     

     

    $

    1,382

     

     

     

     

     

     

     

     

     

     

     

     

    Earnings per diluted share (EPS)

     

    $

    0.28

     

     

    $

    0.04

     

     

    600

    %

    Adjusted EPS

     

    $

    0.21

     

     

    $

    0.17

     

     

    24

    %

    Diluted weighted average shares outstanding

     

     

    32,591,973

     

     

     

    31,658,085

     

     

     

     

     

     

     

     

     

     

    Adjusted EBITDA

     

    $

    12,143

     

     

    $

    7,584

     

     

    60

    %

    A reconciliation of Adjusted EPS and Adjusted EBITDA to the nearest comparable GAAP figures can be found in the schedules included in this release.

    Revenues for the year ended December 31, 2022 increased 25% compared to the prior-year period; 28% on a constant currency basis.

    Gross margin of 61% for the year ended December 31, 2022 was up compared to 59% for the year ended December 31, 2021. Operating loss of $1.9 million for the year ended December 31, 2022, decreased compared to operating loss of $2.6 million for the year ended December 31, 2021.

    Net income was $9.3 million, or $0.28 per fully diluted share, for the year ended December 31, 2022, compared to a net income of $1.4 million, or $0.04 per fully diluted share, for the year ended December 31, 2021. Adjusted EPS was $0.21 for the year ended December 31, 2022, compared to $0.17 for the year ended December 31, 2021.

    Adjusted EBITDA was $12.1 million for the year ended December 31, 2022, compared to $7.6 million for the year ended December 31, 2021.

    Q4 Business Highlights

    • Closed multiple, new, large and recurring OEM accounts
    • Won multiple, large contracts for our fiber sensing solutions in the infrastructure and energy industries
    • Achieved strong, 47% year-over-year growth for the Company's Terahertz products
    • Record quarter in the Company's Communications test vertical, delivering 59% year-over-year revenue growth
    • Delivered a new generation laser tester for Silicon Photonics applications

    2023 Full-Year Outlook

    For fiscal year and Q1 2023, Luna expects:

    • Total revenues in the range of $125 million to $130 million for full year 2023
    • Adjusted EBITDA in the range of $14 million to $18 million for full year 2023
    • Total revenues in the range of $23 million to $25 million for Q1 2023

    Luna is not providing an outlook for net income, which is the most directly comparable GAAP measure to Adjusted EBITDA, because changes in the items that Luna excludes from net income to calculate Adjusted EBITDA, such as share-based compensation, tax expense, and significant non-recurring charges, among other things, can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Luna's routine operating activities.

    The outlook above does not include any future acquisitions, divestitures, or unanticipated events.

    Non-GAAP Financial Measures

    In evaluating the operating performance of its business, Luna's management considers Adjusted EBITDA, Adjusted EPS and revenue measured on a constant currency basis, which are non-GAAP financial measures. Adjusted EBITDA and Adjusted EPS exclude certain charges and income that are required by GAAP. Adjusted EBITDA and Adjusted EPS provide useful information to both management and investors by excluding the effect of certain non-cash expenses and items that Luna believes may not be indicative of its operating performance, because either they are unusual and Luna does not expect them to recur in the ordinary course of its business, or they are unrelated to the ongoing operation of the business in the ordinary course.

    The Company calculates revenue measured on a constant currency basis by translating its foreign revenues for the relevant period in U.S. dollars at the average exchange rate in effect for the comparable prior year period. The Company presents revenue in this manner because it is a global company that transacts business in multiple currencies and reports financial information in U.S. dollars. Foreign currency exchange rate fluctuations affect the amounts reported by the Company in U.S. dollars with respect to its foreign revenues. Exchange rate fluctuations can have a significant effect on reported revenues. The Company believes presenting constant currency revenue information provides useful information to investors, as it provides information to assess how its businesses performed excluding the effects of changes in foreign currency exchange rates and assists investors in evaluating the effectiveness of the Company's operations and underlying business trends in a manner that is consistent with management's evaluation of business performance.

    Adjusted EBITDA, Adjusted EPS and revenue measured on a constant currency basis should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Adjusted EBITDA and Adjusted EPS have been reconciled to the nearest GAAP measure in the table following the financial statements attached to this press release.

    Conference Call Information

    As previously announced, Luna will conduct an investor conference call at 5:00 pm (ET) today to discuss its financial results for the three months and full-year ended December 31, 2022. The investor conference call will be available via live webcast on the Luna website at www.lunainc.com under the tab "Investor Relations." To participate by telephone, the domestic dial-in number is 1.877.270.2148 and the international dial-in number is 1.412.902.6510. Participants should ask to join the Luna Innovations Incorporated conference call and are advised to dial in at least fifteen minutes prior to the call. A replay of the conference call will be available on the company's website under "Webcasts and Presentations" for 30 days following the conference call.

    About Luna

    Luna Innovations Incorporated (www.lunainc.com) is a leader in optical technology, providing unique capabilities in high-performance, fiber optic-based, test products for the telecommunications industry and distributed fiber optic-based sensing for a multitude of industries. Luna's business model is designed to accelerate the process of bringing new and innovative technologies to market.

    Forward-Looking Statements

    The statements in this release that are not historical facts constitute "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements include Luna's expectations regarding its projected 2023 financial results and outlook and growth potential, as well as potential organizational optimization, large customer wins and market expansion. Management cautions the reader that these forward-looking statements are only predictions and are subject to a number of both known and unknown risks and uncertainties, and actual results, performance, and/or achievements of Luna may differ materially from the future results, performance, and/or achievements expressed or implied by these forward-looking statements as a result of a number of factors. These factors include, without limitation, failure of demand for Luna's products and services to meet expectations, failure of target market to grow and expand, technological and strategic challenges, uncertainties related to the ultimate impact of the COVID-19 pandemic and those risks and uncertainties set forth in Luna's Form 10-Q for the quarter ended September 30, 2022, and Luna's other periodic reports and filings with the Securities and Exchange Commission ("SEC"). Such filings are available on the SEC's website at www.sec.gov and on Luna's website at www.lunainc.com. The statements made in this release are based on information available to Luna as of the date of this release and Luna undertakes no obligation to update any of the forward-looking statements after the date of this release.

    Luna Innovations Incorporated

    Consolidated Balance Sheets

    (in thousands of U.S Dollars)

     

     

    December 31, 2022

     

    December 31, 2021

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    6,024

     

     

    $

    17,128

     

    Accounts receivable, net

     

    33,249

     

     

     

    20,913

     

    Contract assets

     

    7,691

     

     

     

    5,166

     

    Inventory

     

    36,582

     

     

     

    22,493

     

    Prepaid expenses and other current assets

     

    4,328

     

     

     

    3,793

     

    Assets held for sale

     

    —

     

     

     

    12,952

     

    Total current assets

     

    87,874

     

     

     

    82,445

     

    Property and equipment, net

     

    4,893

     

     

     

    2,988

     

    Intangible assets, net

     

    18,750

     

     

     

    17,177

     

    Goodwill

     

    26,927

     

     

     

    18,984

     

    Operating lease right-of-use assets

     

    4,661

     

     

     

    5,075

     

    Other non-current assets

     

    3,255

     

     

     

    247

     

    Deferred tax assets

     

    4,647

     

     

     

    3,321

     

    Total assets

     

    151,007

     

     

     

    130,237

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Current portion of long-term debt obligation

    $

    2,500

     

     

    $

    4,167

     

    Accounts payable

     

    8,109

     

     

     

    2,809

     

    Accrued and other current liabilities

     

    16,694

     

     

     

    9,258

     

    Contract liabilities

     

    4,089

     

     

     

    4,649

     

    Current portion of operating lease liabilities

     

    2,239

     

     

     

    2,101

     

    Liabilities associated with assets held for sale

     

    —

     

     

     

    9,703

     

    Total current liabilities

     

    33,631

     

     

     

    32,687

     

    Long-term debt obligation

     

    20,726

     

     

     

    11,673

     

    Long-term portion of operating lease liabilities

     

    2,804

     

     

     

    3,509

     

    Other long-term liabilities

     

    444

     

     

     

    445

     

    Total liabilities

     

    57,605

     

     

     

    48,314

     

    Stockholders' equity:

     

     

     

    Common stock, par value $0.001, 100,000,000 shares authorized, 34,901,954 and 33,855,725 shares issued, 33,105,080 and 32,116,270 shares outstanding at December 31, 2022 and 2021, respectively

     

    35

     

     

     

    34

     

    Treasury stock at cost, 1,796,862 and 1,744,206 shares at December 31, 2022 and 2021, respectively

     

    (5,607

    )

     

     

    (5,248

    )

    Additional paid-in capital

     

    104,893

     

     

     

    98,745

     

    Accumulated deficit

     

    (2,296

    )

     

     

    (11,575

    )

    Accumulated other comprehensive loss

     

    (3,623

    )

     

     

    (33

    )

    Total stockholders' equity

     

    93,402

     

     

     

    81,923

     

    Total liabilities and stockholders' equity

    $

    151,007

     

     

    $

    130,237

     

    Luna Innovations Incorporated

    Consolidated Statements of Operations

    (in thousands of U.S. Dollars, except per share data)

     

     

    Three months ended December 31,

     

    Year ended December 31,

     

     

    2022

     

     

     

    2021

     

     

     

    2022

     

     

     

    2021

     

     

     

     

     

     

     

     

     

    Revenues

    $

    31,702

     

     

    $

    24,222

     

     

    $

    109,497

     

     

    $

    87,513

     

    Cost of revenues

     

    12,367

     

     

     

    10,102

     

     

     

    43,000

     

     

     

    35,957

     

    Gross profit

     

    19,335

     

     

     

    14,120

     

     

     

    66,497

     

     

     

    51,556

     

    Operating expense:

     

     

     

     

     

     

     

    Selling, general and administrative

     

    15,017

     

     

     

    10,542

     

     

     

    57,544

     

     

     

    43,956

     

    Research, development and engineering

     

    2,854

     

     

     

    2,543

     

     

     

    10,837

     

     

     

    10,190

     

    Total operating expense

     

    17,871

     

     

     

    13,085

     

     

     

    68,381

     

     

     

    54,146

     

    Operating income/(loss)

     

    1,464

     

     

     

    1,035

     

     

     

    (1,884

    )

     

     

    (2,590

    )

    Other (expense)/income:

     

     

     

     

     

     

     

    Other income

     

    8

     

     

     

    —

     

     

     

    216

     

     

     

    —

     

    Investment income

     

    —

     

     

     

    —

     

     

     

    46

     

     

     

    —

     

    Interest expense, net

     

    (348

    )

     

     

    (104

    )

     

     

    (898

    )

     

     

    (479

    )

    Total other expense

     

    (340

    )

     

     

    (104

    )

     

     

    (636

    )

     

     

    (479

    )

    Income/(loss) from continuing operations before income taxes

     

    1,124

     

     

     

    931

     

     

     

    (2,520

    )

     

     

    (3,069

    )

    Income tax (expense)/benefit

     

    (307

    )

     

     

    544

     

     

     

    220

     

     

     

    1,980

     

    Income/(loss) from continuing operations

     

    817

     

     

     

    1,475

     

     

     

    (2,300

    )

     

     

    (1,089

    )

    Income from discontinued operations, net of income tax expenses

     

    1,108

     

     

     

    100

     

     

     

    1,730

     

     

     

    2,471

     

    (Loss)/gain on sale of discontinued operations, net of tax of income taxes

     

    (1,072

    )

     

     

    —

     

     

     

    9,849

     

     

     

    —

     

    Net income from discontinued operations

     

    36

     

     

     

    100

     

     

     

    11,579

     

     

     

    2,471

     

    Net income

    $

    853

     

     

    $

    1,575

     

     

    $

    9,279

     

     

    $

    1,382

     

    Net income/(loss) per share from continuing operations:

     

     

     

     

     

     

     

    Basic

    $

    0.02

     

     

    $

    0.05

     

     

    $

    (0.07

    )

     

    $

    (0.03

    )

    Diluted

    $

    0.02

     

     

    $

    0.04

     

     

    $

    (0.07

    )

     

    $

    (0.03

    )

    Net loss per share from discontinued operations:

     

     

     

     

     

     

     

    Basic

    $

    —

     

     

    $

    —

     

     

    $

    0.36

     

     

    $

    0.08

     

    Diluted

    $

    —

     

     

    $

    —

     

     

    $

    0.36

     

     

    $

    0.08

     

    Net income per share:

     

     

     

     

     

     

     

    Basic

    $

    0.02

     

     

    $

    0.05

     

     

    $

    0.28

     

     

    $

    0.04

     

    Diluted

    $

    0.02

     

     

    $

    0.05

     

     

    $

    0.28

     

     

    $

    0.04

     

    Weighted average shares (in thousands):

     

     

     

     

     

     

     

    Basic

     

    32,977

     

     

     

    32,014

     

     

     

    32,592

     

     

     

    31,658

     

    Diluted

     

    34,355

     

     

     

    33,666

     

     

     

    32,592

     

     

     

    31,658

     

    Luna Innovations Incorporated

    Consolidated Statements of Cash Flows

    (in thousands of U.S. Dollars)

     

     

     

    Year ended December 31,

     

     

     

    2022

     

     

     

    2021

     

    Cash flows (used in)/provided by operating activities:

     

     

     

     

    Net income

     

    $

    9,279

     

     

    $

    1,382

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

     

    Depreciation and amortization

     

     

    5,449

     

     

     

    4,628

     

    Stock-based compensation

     

     

    4,232

     

     

     

    2,955

     

    Loss on sale and disposal of property and equipment

     

     

    53

     

     

     

    —

     

    Gain from discontinued operations, net of tax

     

     

    (9,849

    )

     

     

    —

     

    Deferred tax benefit

     

     

    (2,363

    )

     

     

    (1,501

    )

    Changes in operating assets and liabilities:

     

     

     

     

    Accounts receivable

     

     

    (9,151

    )

     

     

    113

     

    Contract assets

     

     

    (5,008

    )

     

     

    (1,672

    )

    Inventory

     

     

    (10,028

    )

     

     

    939

     

    Other current assets

     

     

    (386

    )

     

     

    582

     

    Other long-term assets

     

     

    1,108

     

     

     

    —

     

    Accounts payable and accrued expenses

     

     

    6,122

     

     

     

    (3,213

    )

    Contract liabilities

     

     

    1,973

     

     

     

    186

     

    Other long-term liabilities

     

     

    2

     

     

     

    84

     

    Net cash (used in)/provided by operating activities

     

     

    (8,567

    )

     

     

    4,483

     

    Cash flows used in investing activities:

     

     

     

     

    Acquisitions, net of cash acquired

     

     

    (22,085

    )

     

     

    —

     

    Acquisition of property and equipment

     

     

    (2,888

    )

     

     

    (1,412

    )

    Intangible property costs

     

     

    (50

    )

     

     

    (356

    )

    Proceeds from sale of discontinued operations, net

     

     

    13,968

     

     

     

    —

     

    Net cash used in investing activities

     

     

    (11,055

    )

     

     

    (1,768

    )

    Cash flows provided by/(used in) financing activities:

     

     

     

     

    Proceeds from debt obligations

     

     

    24,150

     

     

     

    —

     

    Payments on debt obligations

     

     

    (16,763

    )

     

     

    (4,144

    )

    Payments on finance lease obligation

     

     

    (48

    )

     

     

    (48

    )

    Purchase of treasury stock

     

     

    (359

    )

     

     

    (459

    )

    Proceeds from ESPP

     

     

    944

     

     

     

    1,131

     

    Proceeds from the exercise of options

     

     

    1,588

     

     

     

    2,256

     

    Net cash provided by/(used in) financing activities

     

     

    9,512

     

     

     

    (1,264

    )

    Net change in cash and cash equivalents

     

     

    (10,110

    )

     

     

    1,451

     

    Effect of exchange rate changes on cash and cash equivalents

     

     

    (994

    )

     

     

    311

     

    Cash and cash equivalents—beginning of period

     

     

    17,128

     

     

     

    15,366

     

    Cash and cash equivalents—end of period

     

    $

    6,024

     

     

    $

    17,128

     

    Supplemental disclosure of cash flow information

     

     

     

     

    Cash paid for interest

     

    $

    805

     

     

    $

    458

     

    Net cash received for income taxes

     

    $

    39

     

     

    $

    113

     

    Luna Innovations Incorporated

    Reconciliation of Net Income to Adjusted EBITDA

    (in thousands)

     

     

    Three months ended

    December 31,

     

    Year ended

    December 31,

     

     

    2022

     

     

     

    2021

     

     

     

    2022

     

     

     

    2021

     

     

     

     

     

    Net income

    $

    853

     

     

    $

    1,575

     

     

    $

    9,279

     

     

    $

    1,382

     

    Income from discontinued operations, net of income taxes

     

    36

     

     

     

    100

     

     

     

    11,579

     

     

     

    2,471

     

    Net income/(loss) from continuing operations

     

    817

     

     

     

    1,475

     

     

     

    (2,300

    )

     

     

    (1,089

    )

    Interest expense

     

    293

     

     

     

    104

     

     

     

    735

     

     

     

    479

     

    Income tax provision/(benefit)

     

    307

     

     

     

    (544

    )

     

     

    (220

    )

     

     

    (1,980

    )

    Depreciation and amortization (1)

     

    1,455

     

     

     

    1,077

     

     

     

    5,449

     

     

     

    4,517

     

    EBITDA

     

    2,872

     

     

     

    2,112

     

     

     

    3,664

     

     

     

    1,927

     

    Share-based compensation (1)

     

    1,067

     

     

     

    693

     

     

     

    4,094

     

     

     

    2,826

     

    Integration and transaction expense

     

    (21

    )

     

     

    249

     

     

     

    2,163

     

     

     

    2,322

     

    Amortization of inventory step-up

     

    286

     

     

     

    69

     

     

     

    677

     

     

     

    509

     

    Other non-recurring charges (2)

     

    488

     

     

     

    —

     

     

     

    1,545

     

     

     

    —

     

    Adjusted EBITDA

    $

    4,692

     

     

    $

    3,123

     

     

    $

    12,143

     

     

    $

    7,584

     

     

    (1) Excludes portion classified in discontinued operations.

    (2) Other non-recurring charges include severance, customer accommodation, facility consolidation and debt refinancing costs.

    Luna Innovations Incorporated

    Reconciliation of Net Income to Adjusted EPS

    (in thousands, except share and per share data)

     

     

    Three months ended

    December 31,

     

    Year ended

    December 31,

     

     

    2022

     

     

     

    2021

     

     

     

    2022

     

     

     

    2021

     

     

     

     

     

    Net income

    $

    853

     

     

    $

    1,575

     

     

    $

    9,279

     

     

    $

    1,382

     

    Income from discontinued operations, net of income taxes

     

    36

     

     

     

    100

     

     

     

    11,579

     

     

     

    2,471

     

    Net income/(loss) from continuing operations

     

    817

     

     

     

    1,475

     

     

     

    (2,300

    )

     

     

    (1,089

    )

    Share-based compensation (1)

     

    1,067

     

     

     

    693

     

     

     

    4,094

     

     

     

    2,826

     

    Integration and transaction expense

     

    (21

    )

     

     

    249

     

     

     

    2,163

     

     

     

    2,322

     

    Amortization of intangible assets (1)

     

    952

     

     

     

    760

     

     

     

    3,745

     

     

     

    3,113

     

    Amortization of inventory step-up

     

    286

     

     

     

    69

     

     

     

    677

     

     

     

    509

     

    Other non-recurring charges (2)

     

    488

     

     

     

    —

     

     

     

    1,545

     

     

     

    —

     

    Income tax effect on adjustments

     

    (693

    )

     

     

    (443

    )

     

     

    (3,056

    )

     

     

    (2,193

    )

    Adjusted income from continuing operations

    $

    2,896

     

     

    $

    2,803

     

     

    $

    6,868

     

     

    $

    5,488

     

     

     

     

     

     

     

     

     

    Adjusted EPS

    $

    0.08

     

     

    $

    0.08

     

     

    $

    0.21

     

     

    $

    0.17

     

     

     

     

     

     

     

     

     

    Adjusted weighted average shares:

     

     

     

     

     

     

     

    Diluted

     

    34,355

     

     

     

    33,666

     

     

     

    32,592

     

     

     

    31,658

     

     

    (1) Excludes portion classified in discontinued operations.

    (2) Other non-recurring charges include severance, customer accommodation, facility consolidation and debt refinancing costs.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005906/en/

    Get the next $LUNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Updates on Operating Metrics and Intent to Deregister Stock

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announces an update on select operating metrics. The Company is also communicating its intent to voluntarily accelerate its delisting from Nasdaq and ultimately deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including suspending its reporting obligations under Section 15(d) of the Exchange Act. The accelerated delisting and deregistration process will not adversely affect Luna's ongoing operations or the listing of the Company's common stock on the OTC Experts Market. "Luna star

      1/27/25 10:24:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Stock to Be Suspended from Nasdaq Listing

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, due to the Company's inability to meet the March 27, 2025 deadline to file its previously disclosed delinquent filings with the Securities and Exchange Commission to regain compliance, the trading in its securities will be suspended tomorrow, January 7, 2025, and subsequently delisted from The Nasdaq Stock Market LLC ("Nasdaq"). Following the suspension, the Company expects its shares to be eligible to trade on the over-the-counter ("OTC") market, specifically the OTC Expert Market. The suspension/delisting of the Company's stock from Nasdaq does not

      1/6/25 8:30:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    SEC Filings

    See more
    • Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/27/25 10:26:44 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

      SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      1/14/25 1:56:29 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/6/25 8:30:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Luna Innovations with a new price target

      Stifel initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $12.50

      7/28/23 7:35:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Needham initiated coverage on Luna Innovations with a new price target

      Needham initiated coverage of Luna Innovations with a rating of Buy and set a new price target of $10.00

      5/22/23 7:57:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations downgraded by Northland Capital with a new price target

      Northland Capital downgraded Luna Innovations from Outperform to Market Perform and set a new price target of $8.00

      3/15/23 8:52:49 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 12:32:28 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed by Luna Innovations Incorporated

      SC 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/14/24 8:39:20 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Luna Innovations Incorporated

      SC 13G/A - LUNA INNOVATIONS INC (0001239819) (Subject)

      11/12/24 4:02:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:44:17 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Anderson N Leigh converted options into 19,869 shares, increasing direct ownership by 122% to 36,102 units (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      1/3/25 4:43:48 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Coe Pamela L converted options into 13,372 units of Common Stock (SEC Form 4)

      4 - LUNA INNOVATIONS INC (0001239819) (Issuer)

      12/26/24 5:52:51 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Resignation of Pamela Coe

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced that, Pamela Coe, a member of the Board of Directors (the "Board"), will be retiring from the Luna board effective today. Ms. Coe was elected to the Board in May 2021 for a three-year term. "We are very grateful for Pam's notable contributions and leadership throughout her time on the Board," said Barry Phelps, Chairman of the Board of the Company. "Her expertise, focus and commitment have been instrumental in guiding Luna. We wish Pam all the best in her future endeavors." About Luna Luna Innovations Incorporated (www.lunainc.com) is a leader in optic

      12/27/24 4:40:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces CFO Transition: Names William Phelan as Chief Financial Officer and Chief Accounting Officer

      Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the appointment of William L. Phelan as its new Chief Financial Officer and Chief Accounting Officer, effective immediately. Mr. Phelan succeeds John Roiko, who joined Luna out of retirement in May 2024 and played a key role in establishing a resilient foundation for Luna's future growth. Following the appointment of Mr. Phelan, Mr. Roiko will shift to a consulting role to support the ongoing restatement process. "We are delighted to welcome Bill to the Luna leadership team," said Kevin Ilcisin, President and CEO of Luna. "Bill's highly relevant experience will be instrume

      10/16/24 4:30:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Financials

    Live finance-specific insights

    See more
    • Luna Innovations to Delay Release of Fourth Quarter and Full Year 2023 Financial Results

      Luna Innovations Incorporated (NASDAQ:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announced it will delay the release of its fourth quarter and fiscal year 2023 financial results and the subsequent conference call. A Special Committee of the Company's Board of Directors is conducting an independent review, with the assistance of external legal and financial advisors, of certain transactions for which revenue was recognized in the second and third quarters of 2023 that did not qualify for revenue recognition under U.S. generally accepted accounting principles. The Special Committee is examining the circumstances surrounding these issues and is eva

      3/12/24 4:20:00 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces $50 Million Strategic Investment from White Hat Capital Partners

      Investment Proceeds Used to Fund Silixa Acquisition and Enhance Luna's Financial Flexibility to Pursue Strategic Growth Initiatives Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced a $50 million investment by White Hat Capital Partners ("White Hat"), an investment firm focused on sustainable value creation in technology companies serving mission-critical applications. Proceeds from this strategic investment were partially used to fund the acquisition of Silixa, also announced today, and related transaction costs in the aggregate amount of approximately $25 million. Remaining proceeds were used to repay the Company's o

      12/21/23 9:34:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Acquires Silixa

      Strengthens Portfolio of Distributed Fiber Optic Sensing Solutions Adds Significant New Growth Markets and Applications and Further Expands Global Footprint Conference Call Scheduled for Today, December 21st, at 11:00 AM ET Luna Innovations Incorporated (NASDAQ:LUNA), a global leader in advanced fiber optic-based technology, today announced the strategic acquisition of Silixa, a UK-based leader in distributed fiber optic sensing solutions. The acquisition further propels Luna's position in the fiber optic sensing market, adding capabilities in distributed acoustic sensing (DAS), distributed temperature sensing (DTS) and distributed strain sensing (DSS) that offer enhanced performance

      12/21/23 9:32:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care